Drug recall · April 12, 2017
RIVASTIGMINE Tartrate Capsules recall
Why: Cross-contamination with other products -Related Substances test for Rivastigmine Tartrate Capsules USP, 1.5 mg showed a peak for Ranitidine.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
RIVASTIGMINE Tartrate Capsules, USP, 1.5 mg, 60-count bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachupally 500-900 India, NDC 55111-352-60
- Lots / codes
Lot #C607323, Exp 10/18
- Quantity
- 1,728 bottles
- Company
- Dr. Reddy's Laboratories, Inc., Princeton, NJ
- Distribution
- U.S. nationwide
- Initiated
- March 6, 2017 · Voluntary: Firm initiated
- Classified
- April 6, 2017
- Reported
- April 12, 2017
- Ended
- December 21, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Rivastigmine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.